Document is current
Any future updates will be listed below
-
Authors
Aggarwal, Brooke https://orcid.org/0000-0002-6199-864X
Gao, Yunling https://orcid.org/0000-0002-6622-3253
Alfini, Alfonso
Azarbarzin, Ali https://orcid.org/0000-0002-4986-4753
Anafi, Ron C.
Glazer Baron, Kelly
Bautch, Victoria L.
Bowles, Nicole
Broussard, Josiane L.
Brown, Marishka
Cheng, Philip
Cook, Stephanie H.
Cortese, Rene https://orcid.org/0000-0001-9262-7828
Fernandez, Fabian-Xosé
Galis, Zorina
Johnson, Dayna A.
Jelic, Sanja
Lipton, Jonathan O. https://orcid.org/0000-0002-9648-0541
Lutsey, Pamela L. https://orcid.org/0000-0002-1572-1340
Miao, Qing
Ordovas, Jose M. https://orcid.org/0000-0002-7581-5680
Prather, Aric A.
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
Tasali, Esra
Vargas, Ivan
Grandner, Michael A.
Lloyd-Jones, Donald
- License Information
-
More Information
Article History
Accepted: 30 June 2025
First Online: 18 September 2025
Competing interests
: The views expressed in this article are those of the authors and reflect those of the workshop, and do not necessarily represent those of the NHLBI, the NIH, or the US Department of Health and Human Services. No industry support was used for this project. A. Azarbarzin is a consultant for Apnimed, Cerebra, Eli Lilly, Inspire and Respicardia. D.A.J. has received consulting fees from Idorsia Pharmaceuticals. J.O.L. has received consulting fees from Synchronicity Pharma. E.T. is an adviser to NeuroGeneCES and Vitaliti. The other authors declare no competing interests.
